Management of Established Surgical Site Infections

Surgical Infections

Volumn 7, Issue , 2006, Pages s-33-s-41

  Turina, Matthias ^a   Cheadle, William G ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49249087313     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2006.7.s3-33     Document Type: Article

References (44)

1. Altemeier W. A. Sepsis in surgery. Presidential address. Arch Surg 1982;117:107–112.
2. Barie P. S., Surgical site infections: Epidemiology and prevention. Surg Infect 2002;3(Suppl 1):S9–21.
3. Horan T. C., Gaynes R. P., Martone W. J., et al. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992;13: 606–608.
4. McHenry C. R., Piotrowski J. J., Petrinic D., et al. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558–563.
5. Freischlag J. A., Ajalat G., Busuttil R. W. Treatment of necrotizing soft tissue infections: The need for a new approach. Am J Surg 1985;149:751–755.
6. Fry D. E. Infections of the skin and soft tissues. In: Fry D., ed. Surgical Infections. Boston. Little, Brown and Company, 1994:145–226.
7. Carroll J. A. Common bacterial pyodermas: Taking aim against the most likely pathogens. Postgrad Med 1996;100:311–322.
8. Fitzpatrick T. B., Eisen A. Z., Wolff K. F. I. M., et al. Dermatology in General Medicine. New York: McGraw-Hill, 1987.
9. O'Dell M. L. Skin and wound infections: An overview. Am Fam Physician 1998;57:2424–2432.
10. Seal D. V. Necrotizing fasciitis. Curr Opin Infect Dis 2001;14:127–132.
11. Cox N. H. Streptococcal necrotizing fasciitis and the dermatologist. Br J Dermatol 1999;141:613–614.
12. Rouse T. M., Malangoni M. A., Schulte W. J. Necrotizing fasciitis: A preventable disaster. Surgery 1982;92:765–770.
13. Sudarsky L. A., Laschinger J. C., Coppa G. F., et al. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg 1987;206:661–665.
14. Jallali N., Withey S., Butler P. E. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005;189:462–466.
15. Morykwas M. J., Argenta L. C., Shelton-Brown E. I., et al. Vacuum-assisted closure: A new method for wound control and treatment: Animal studies and basic foundation. Ann Plast Surg 1997;38:553–562.
16. Morykwas M. J., Simpson J., Punger K., et al. Vacuum-assisted closure: State of basic research and physiologic foundation. Plast Reconstr Surg 2006;117:121S-126S.
17. Venturi M. L., Attinger C. E., Mesbahi A. N., et al. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) device: A review. Am J Clin Dermatol 2005;6:185–194.
18. Heller L., Levin S. L., Butler C. E. Management of abdominal wound dehiscence using vacuum assisted closure in patients with compromised healing. Am J Surg 2006;191:165–172.
19. Schaffzin D. M., Douglas J. M., Stahl T. J., et al. Vacuum-assisted closure of complex perineal wounds. Dis Colon Rectum 2004;47:1745–1748.
20. Scherer L. A., Shiver S., Chang M., et al. The vacuum assisted closure device: A method of securing skin grafts and improving graft survival. Arch Surg 2002;137:930–933.
21. Sjogren J., Nilsson J., Gustafsson R., et al. The impact of vacuum-assisted closure on long-term survival after post-sternotomy mediastinitis. Ann Thorac Surg 2005;80:1270–1275.
22. Stonerock C. E., Bynoe R. P., Yost M. J., et al. Use of a vacuum-assisted device to facilitate abdominal closure. Am Surg 2003;69:1030–1034.
23. Suliburk J. W., Ware D. N., Balogh Z., et al. Vacuum-assisted wound closure achieves early fascial closure of open abdomens after severe trauma. J Trauma 2003;55:1155–1160.
24. Raghavan M., Linden P. K. Newer treatment options for skin and soft tissue infections. Drugs 2004;64: 1621–1642.
25. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2004; issued October 2004. Am J Infect Control 2004; 32:470–485.
26. Martin S. J., Zeigler D. G. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004;5:237–246.
27. Paterson D. L. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-S345.
28. Franklin G. A., Moore K. B., Snyder J. W., et al. Emergence of resistant microbes in critical care units is transient, despite an unrestricted formulary and multiple antibiotic trials. Surg Infect 2002;3:135–144.
29. Lee S. Y., Kuti J. L., Nicolau D. P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect 2005; 6:283–295.
30. Nichols R. L., Graham D. R., Barriere S. L., et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44:263–273.
31. Stevens D. L., Dotter B., Madaras-Kelly K. A review of linezolid: The first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2:51–59.
32. Weigelt J., Kaafarani H. M., Itani K. M., et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760–766.
33. Arbeit R. D., Maki D., Tally F. P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–1681.
34. Guay D. R. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004;24:58–68.
35. Betriu C., Culebras E., Rodriguez-Avial I., et al. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004;48:323–325.
36. Fritsche T. R., Jones R. N. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 2004;24:567–571.
37. Fritsche T. R., Kirby J. T., Jones R. N. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004;49:201–209.
38. Jacobus N. V., McDermott L. A., Ruthazer R., et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48:1034–1036.
39. Kitzis M. D., Ly A., Goldstein F. W. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:366–367.
40. Fabian T. C., File T. M., Embil J. M., et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: Results of a multicenter, randomized, double-blind comparative study. Surg Infect 2005;6: 269–282.
41. Graham D. R., Lucasti C., Malafaia O., et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002;34:1460–1468.
42. Keating G. M., Perry C. M. Ertapenem: A review of its use in the treatment of bacterial infections. Drugs 2005;65:2151–2178.
43. Betriu C., Salso S., Sanchez A., et al. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 2006;28:1–5.
44. Chen M., Nafziger A. N., Drusano G. L., et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006;50:1222–1227.